Uromigos-Kidney Cancer
Advertisement
Dr. David Braun discusses his organization of immune therapies into four groups and describes novel treatments and targets.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon host the first Spanish-language ASCO episode for The Uromigos.
Drs. Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden get a chance to win The Uromigos Cup.
Drs. Viktor Grünwald, Boris Hadaschik and Gunhild Von Amsberg answer trivia for the Uromigos Cup qualifying round.
Drs. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura answer trivia questions set by Tom and Brian for the Uromigos Cup.
Drs. Danny Heng, Christian Kollmannsberger and Kala Sridhar attempt to take on Team LA to win the Uromigos Cup.
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564.
Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments.
Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data.
Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC.
Cristina Suarez discusses the biggest RCC trials of 2023.
Tian Zhang joins the podcast to give an overview of some of the panels presented at this year's IKCS meeting.
Xinan Sheng, MD, joins the podcast to discuss the RENOTORCH trial on toripalimab plus axitinib for advanced RCC.
Dr. Lisa Pickering discusses 3 different renal cancer abstracts that were presented at ESMO 2023.
Dr. Toni Choueiri discusses progress in systemic therapy for papillary renal cell carcinoma, as well as personalized therapy.
Dr. Celeste Simon discusses her career in translational science and kidney cancer at the University of Pennsylvania.
Dr. Laurence Albiges discusses biomarker studies and new combinations and therapies presented at the KCRS23 meeting.
Rachel Giles, MD, PhD, describes her patient data on adjuvant and first line treatments in renal cell carcinoma.
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.